AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21544313 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 120 mg
Number of subjects: 100
Study 21544313 — intervention group
Group type: COMPARATOR
Intervention: fondaparinux 2.5 mg
Number of subjects: 100
Study 21544313 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 19246254 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride determination method using high-performance liquid chromatography with fluorimetric detection
Number of subjects: 0
Study 19246254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence study samples
Number of subjects: 0
Study 17956811 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory discrimination therapy (ADT)
Number of subjects: 27
Study 17956811 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin photoaging assessment using the Larnier skin photoaging photographic scale.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a variable related to skin photoaging in women.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototype as a variable related to skin photoaging in women.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal status as a variable related to skin photoaging in women.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic location as a variable related to skin photoaging in women.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a variable related to skin photoaging in men.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic location as a variable related to skin photoaging in men.
Number of subjects: 9363
Study 10607319 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototype as a variable related to skin photoaging in men.
Number of subjects: 9363
Study 9162303 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.125 g/day
Number of subjects: 76
Study 9162303 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.25 g/day
Number of subjects: 76
Study 9162303 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/day
Number of subjects: 76
Study 9162303 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 1.0 g/day
Number of subjects: 76
Study 9162303 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO doses of > or = 1 g/day
Number of subjects: 76
Study 1995527 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 8.0 Gy
Number of subjects: 137
Study 1995527 — intervention group
Group type: COMPARATOR
Intervention: 20 x 2.5 Gy
Number of subjects: 137
Study 6390823 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 299
Study 6390823 — intervention group
Group type: COMPARATOR
Intervention: Nonsplenectomy
Number of subjects: 299
Study 30826791 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental growth factor testing (unblinded point of care test)
Number of subjects: 4000
Study 30320677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour group
Number of subjects: 3
Study 30320677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour group
Number of subjects: 3
Study 30320677 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour group
Number of subjects: 3
Study 25864771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scanning (IOS)
Number of subjects: 20
Study 25864771 — intervention group
Group type: COMPARATOR
Intervention: Classical polyether impressions
Number of subjects: 20
Study 24843313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (1 mg) and ketorolac (1.5 mg)
Number of subjects: 81
Study 24843313 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (10 mcg) and ketorolac (1.5 mg)
Number of subjects: 81
Study 24843313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 81
Study 24843313 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 81
Study 24843313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone and Fentanyl
Number of subjects: 81
Study 23122650 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 667
Study 23122650 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta 1a
Number of subjects: 667
Study 20730665 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate online support condition
Number of subjects: 30
Study 20730665 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control condition
Number of subjects: 30
Study 16533870 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg before CS/US pairing
Number of subjects: 42
Study 16533870 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg before conditioning
Number of subjects: 42
Study 16533870 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil 1 mg after conditioning
Number of subjects: 42
Study 16533870 — intervention group
Group type: COMPARATOR
Intervention: Placebo/saline/saline
Number of subjects: 42
Study 16533870 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam/saline/saline
Number of subjects: 42
Study 15448917 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) group
Number of subjects: 478
Study 15448917 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD group
Number of subjects: 478
Study 15448917 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for BPD
Number of subjects: 478
Study 11876690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha-2b (10 MU daily for 10 days, then 5 MU daily for 74 days, then 5 MU three times weekly for 24 weeks)
Number of subjects: 25
Study 11876690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha-2b with ribavirin (1000-1200 mg/day starting at day 11)
Number of subjects: 25
Study 11876690 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon alpha-2b
Number of subjects: 25
Study 10215775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy (200 mg twice daily for 1 week per month for 3 months)
Number of subjects: 129
Study 10215775 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (200 mg once daily for 3 months)
Number of subjects: 129
Study 7759273 — intervention group
Group type: EXPERIMENTAL
Intervention: music therapy
Number of subjects: 96
Study 7759273 — intervention group
Group type: EXPERIMENTAL
Intervention: music-video therapy
Number of subjects: 96
Study 7759273 — intervention group
Group type: COMPARATOR
Intervention: scheduled rest group
Number of subjects: 96
Study 2186658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with fentanyl 100 mcg
Number of subjects: 60
Study 2186658 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% plain
Number of subjects: 60
Study 31940279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromegaly group
Number of subjects: 178
Study 31940279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study 31940279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 178
Study 30681719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length (CL) ≤11 mm
Number of subjects: 119
Study 30681719 — intervention group
Group type: COMPARATOR
Intervention: Cervical length (CL) >11 mm
Number of subjects: 119
Study 29310376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 μg and morphine 100 μg (FM group)
Number of subjects: 60
Study 29310376 — intervention group
Group type: COMPARATOR
Intervention: Morphine 100 μg (M group)
Number of subjects: 60
Study 24986038 — intervention group
Group type: EXPERIMENTAL
Intervention: Qsymia (phentermine 7.5 mg plus topiramate 46.0 mg)
Number of subjects: 93
Study 24986038 — intervention group
Group type: COMPARATOR
Intervention: Diet and lifestyle advice plus placebo
Number of subjects: 93
Study 23159018 — intervention group
Group type: EXPERIMENTAL
Intervention: R-REM training intervention for nursing staff
Number of subjects: 1405
Study 22087680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (2 g per day)
Number of subjects: 227
Study 22087680 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg per kilogram of body weight per day)
Number of subjects: 227
Study 22087680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 227
Study 22087680 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 227
Study 20002061 — intervention group
Group type: COMPARATOR
Intervention: 50 g activated charcoal (control)
Number of subjects: 16
Study 20002061 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g activated charcoal
Number of subjects: 16
Study 20002061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g activated charcoal
Number of subjects: 16
Study 20002061 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g activated charcoal
Number of subjects: 16
Study 17635578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PACAP38 (cumulative dose of 480 microg)
Number of subjects: 12
Study 17635578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PACAP38
Number of subjects: 12
Study 17635578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 15240645 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (replacement of protease inhibitor)
Number of subjects: 8
Study 11777752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact tablet after high-fat breakfast
Number of subjects: 0
Study 11777752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet split into three fragments
Number of subjects: 0
Study 11777752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional dosing (40 mg in the morning and 20 mg in the evening)
Number of subjects: 0
Study 11777752 — intervention group
Group type: COMPARATOR
Intervention: Once daily dosing
Number of subjects: 0
Study 9694707 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg cyanocobalamin orally daily for 120 days
Number of subjects: 38
Study 9694707 — intervention group
Group type: COMPARATOR
Intervention: 1 mg cyanocobalamin intramuscularly on days 1, 3, 7, 10, 14, 21, 30, 60, and 90
Number of subjects: 38
Study 8087823 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) 20 mg b.i.d.
Number of subjects: 214
Study 8087823 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) 5 mg b.i.d.
Number of subjects: 214
Study 8087823 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) 10 mg b.i.d.
Number of subjects: 214
Study 8087823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 2490902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study 2490902 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam
Number of subjects: 0
Study 848618 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by community members trained to take blood pressure measurements (BPMs)
Number of subjects: 800
Study 848618 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive techniques such as invitational letters and gift offers
Number of subjects: 800
Study 848618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior informational letters specifying time of visit
Number of subjects: 800
Study 848618 — intervention group
Group type: COMPARATOR
Intervention: Control group (fifth target area)
Number of subjects: 800
Study 31002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA)
Number of subjects: 35
Study 31002769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PtDA)
Number of subjects: 35
Study 31002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (with PtDA)
Number of subjects: 35
Study 28138158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of low-dose endotoxin (0.8 ng/kg body weight)
Number of subjects: 18
Study 28138158 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 28138158 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin treatment
Number of subjects: 18
Study 25249577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 28
Study 25249577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study 22112682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CR
Number of subjects: 50
Study 22112682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 50
Study 22112682 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 50
Study 22112682 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 50
Study 21761252 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral skin incision
Number of subjects: 69
Study 21761252 — intervention group
Group type: COMPARATOR
Intervention: Midline skin incision
Number of subjects: 69
Study 21761252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 69
Study 21761252 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire group
Number of subjects: 69
Study 19242484 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural support (nesting with rolled-up towels)
Number of subjects: 47
Study 19242484 — intervention group
Group type: COMPARATOR
Intervention: Care model used by the unit (no postural support)
Number of subjects: 47
Study 16479409 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprivan 1%
Number of subjects: 10
Study 16479409 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1% MCT Fresenius
Number of subjects: 10
Study 12548315 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of virgin olive oil (50 ml)
Number of subjects: 7
Study 12548315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained doses of virgin olive oil (25 ml/day for one week)
Number of subjects: 7
Study 10928528 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of metallic stents
Number of subjects: 22
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated implants
Number of subjects: 2212
Study 9477785 — intervention group
Group type: COMPARATOR
Intervention: Uncoated implants
Number of subjects: 2212
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in quality 1 and 2 bone
Number of subjects: 2212
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in quality 3 bone
Number of subjects: 2212
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in quality 4 bone
Number of subjects: 2212
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in the posterior maxilla
Number of subjects: 2212
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Single implants in the anterior maxilla
Number of subjects: 2212
Study 9477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants in other regions
Number of subjects: 2212
Study 8463866 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of albendazole (600 mg, 1x)
Number of subjects: 284
Study 8463866 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of albendazole (600 mg, 2x)
Number of subjects: 284
Study 8463866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 3100707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical score-based timing of hCG administration
Number of subjects: 42
Study 3100707 — intervention group
Group type: COMPARATOR
Intervention: Estradiol and ultrasound-based timing of hCG administration
Number of subjects: 42
Study 3100707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical score
Number of subjects: 42
Study 3100707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical score distribution by estradiol levels
Number of subjects: 42
Study 29529522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 64
Study 29529522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27506866 — intervention group
Group type: COMPARATOR
Intervention: Live tissue training
Number of subjects: 742
Study 27506866 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 742
Study 27506866 — intervention group
Group type: COMPARATOR
Intervention: Fluid resuscitation (psychomotor performance)
Number of subjects: 742
Study 25441567 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 40
Study 25441567 — intervention group
Group type: COMPARATOR
Intervention: Oral steroid therapy
Number of subjects: 40
Study 22532110 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal training
Number of subjects: 16
Study 20422949 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride (150 mg/capsule, test preparation)
Number of subjects: 20
Study 20422949 — intervention group
Group type: COMPARATOR
Intervention: Commercially available original capsule (150 mg/capsule, reference preparation)
Number of subjects: 20
Study 18554394 — intervention group
Group type: EXPERIMENTAL
Intervention: High velocity power training (PT)
Number of subjects: 45
Study 18554394 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training (ST)
Number of subjects: 45
Study 18554394 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 45
Study 15225193 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg once a day
Number of subjects: 337
Study 15225193 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg once a day
Number of subjects: 337
Study 15225193 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid 500 mg three times a day
Number of subjects: 337
Study 15225193 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg and 15 mg
Number of subjects: 337
Study 12167389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg twice daily
Number of subjects: 0
Study 12167389 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice daily
Number of subjects: 0
Study 9524901 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral doses of dolasetron mesylate
Number of subjects: 789
Study 9524901 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral doses of dolasetron mesylate
Number of subjects: 789
Study 9524901 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral doses of dolasetron mesylate
Number of subjects: 789
Study 9524901 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral doses of dolasetron mesylate
Number of subjects: 789
Study 9524901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 789
Study 8591940 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 5 mg/kg od
Number of subjects: 20
Study 8591940 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 2.5 mg/kg bd
Number of subjects: 20
Study 8591940 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 2.5 mg/kg od
Number of subjects: 20
Study 2655676 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese BCG vaccine
Number of subjects: 602
Study 2655676 — intervention group
Group type: COMPARATOR
Intervention: British BCG vaccine
Number of subjects: 602
Study 2655676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 602
Study 1248096 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic device for metered dose release
Number of subjects: 0
Study 29055655 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 200
Study 29055655 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual education by diabetes educators)
Number of subjects: 200
Study 26903254 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABM intervention (n = 23)
Number of subjects: 45
Study 26903254 — intervention group
Group type: COMPARATOR
Intervention: Placebo ABM training (n = 22)
Number of subjects: 45
Study 23963355 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 (250 mg)
Number of subjects: 75
Study 23963355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 75
Study 23963355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22515794 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure intervention (AAP) in addition to standard care (SC)
Number of subjects: 10
Study 22515794 — intervention group
Group type: COMPARATOR
Intervention: Auricular acupressure using sham auricular points (SAP) in addition to standard care (SC)
Number of subjects: 10
Study 22515794 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 10
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow repetition speed (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate repetition speed (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast repetition speed (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 20104178 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study 17469682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions in Alzheimer's disease (AD)
Number of subjects: 0
Study 17469682 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 16393321 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus fermentum PCC)
Number of subjects: 53
Study 16393321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53